Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer?

Annals of Surgical Oncology

Volumn 14, Issue 12, 2007, Pages 3412-3418

  Mansour, John C ^a   Tang, Laura ^a   Shah, Manish ^a   Bentrem, David ^b   Klimstra, David S ^a   Gonen, Mithat ^a   Kelsen, David P ^a   Brennan, Murray F ^a   Coit, Daniel G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Chemotherapy; Gastric cancer; Graded histologic response; Neoadjuvant; Pathologic response

Indexed keywords

ANTIINFECTIVE AGENT; CISPLATIN; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; METHOTREXATE; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER SURGERY; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DATA BASE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LOWER ESOPHAGUS SPHINCTER; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTOR VARIABLE; PROSPECTIVE STUDY; STOMACH CANCER; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; GASTRECTOMY; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 36349007538     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9574-6     Document Type: Article

References (11)

1. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20
2. Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001;8:123-32
3. Onaitis MW, Noone RB, Fields R, et al. Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. Ann Surg Oncol 2001;8:801-6
4. Ruo L, Tickoo S, Klimstra D, et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 2002;236:75-81
5. White RR, Paulson EK, Freed KS, et al. Staging of pancreatic cancer before and after neoadjuvant chemoradiation. J Gastrointest Surg 2001;5:626-33
6. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999;229:303-9
7. Brenner B, Shah MA, Karpeh MS, et al. A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer. Ann Oncol 2006;17:1404-11
8. Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004;22:2774-80
9. Jhawer MP, Gonen M, Brenner B, et al. Post-treatment perineural and vascular invasion (PVI) predicts survival following preoperative therapy for patients with locally advanced gastric cancer (LAGC) (abstract). Paper presented at: ASCO Gastrointestinal Cancers Symposium; 21 January 2007; Orlando, FL
10. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006;24:4692-8
11. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006;12:1294-300